10 Best Performing S&P 500 Stocks So Far in 2026
On April 22, Andrew Slimmon, Morgan Stanley Investment Management Senior Portfolio Manager, joined CNBC's 'Squawk Box' to discuss the latest market trends.
Moderna Inc. (MRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 3,906 | $198,425 | -83% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | $1,812,754.29 | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | $3,191,563.84 | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | $1,004,251.20 | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | $999,989.00 | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $52.29 | 13,885 | $726,046.65 | 59,689 | 2026-03-02 | Filing | |
| $48.84 | 160,009 | $7,814,839.56 | 1,457,427 | 2026-02-23 | Filing | |
| $29.49 | 23,853 | $703,305.71 | 3,924 | 2025-12-11 | Filing | |
| $27.60 | 504 | $13,910.40 | 1,515 | 2025-12-09 | Filing | |
| $28.00 | 312 | $8,736.00 | 580 | 2025-06-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,748,754 | $139,636,703 | 0.98% | |
| 2. | 1,311,480 | $66,623,184 | 0.96% | |
| 3. | 1,078,194 | $54,772,255 | 0.01% | |
| 4. | 676,117 | $32,789,686 | 0.03% | |
| 5. | 490,088 | $24,632,372 | 0.01% |
News See All
Jim Cramer’s 19 Stock Q1 Recap: S&P 500 Winners vs. Nasdaq 100’s Worst Performers
In this article, we will look at Jim Cramer’s review of the S&P 500’s top performers and the Nasdaq 100’s biggest laggards for the first quarter.
Moderna (MRNA) Climbs 16% as Arbutus-Genevant Legal Battle Clears
Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after resolving a four-year legal dispute with two biopharmaceutical companies in relation to an ...
Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves
On January 28, Barclays assumed coverage of Moderna, Inc. (NASDAQ:MRNA) with an Equal Weight rating and a $25 price target as part of a broader biotechnology coverage expansion.
10 Best Long Term Healthcare Stocks to Buy
Investing in healthcare stocks offers a combination of defensive stability and long-term growth potential, supported by consistent demand for medical services, pharmaceuticals, and healthcare technologies...
What Does the Street Think About Moderna, Inc. (MRNA)?
Moderna, Inc. (NASDAQ:MRNA) is one of the best healthcare stocks under $50 to invest in. Morgan Stanley reiterated a Hold rating on Moderna, Inc.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.
Jim Cramer’s Game Plan: 19 Stocks in Focus
I don't usually start the game plan on Wednesday, but that's when we get the employment report this time, and it's kind of screwed up because of the government shutdown.
Jim Cramer Highlighted 16 Noteworthy S&P 500 Stocks
The first month of 2026 is officially in the books. So before we move on to another very busy week of earnings, I want to go over the state of the market.
Jim Cramer Was Recently Asked About These 9 Stocks
I never thought I'd say this, but the United States increasingly feels like a command economy where you better accept the president's terms without complaints or suffer the consequences, which could be...
Hedge Fund Resource Center